El interés en corto de Anixa Biosciences da a los inversores una idea del grado en que los inversores apuestan por la caída de las acciones de Anixa Biosciences. Los datos de interés en corto se actualizan cada dos semanas.

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Informe de interés en corto

Anixa Biosciences

Anixa Biosciences Inc, a cancer-focused biotechnology company, developing vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.

Anixa Biosciences Inc

<p>Deep-pocketed investors have adopted a bullish approach towards Trade Desk (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTD#NASDAQ">TTD</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in TTD usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 20 extraordinary options activities for Trade Desk. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 60% leaning bullish and 30% bearish. Among these notable options, 16 are puts, totaling $802,286, and 4 are calls, amounting to $156,510.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $110.0 to $170.0 for Trade Desk during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In terms of liquidity and interest, the mean open interest for Trade Desk options trades today is 493.67 with a total volume of 5,958.00.</p>
<p>In the following chart, we are able to follow the development of volume and open interest of call and put options for Trade Desk's big money trades within a strike price range of $110.0 to $170.0 over the last 30 days.</p>
<h3>Trade Desk 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968728_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.0</td>
<td>$7.8</td>
<td>$7.8</td>
<td>$120.00</td>
<td>$155.2K</td>
<td align="right">55</td>
<td align="right">0</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/24/25</td>
<td>$5.2</td>
<td>$4.5</td>
<td>$4.5</td>
<td>$120.00</td>
<td>$67.5K</td>
<td align="right">99</td>
<td align="right">150</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$4.35</td>
<td>$4.05</td>
<td>$4.35</td>
<td>$110.00</td>
<td>$65.2K</td>
<td align="right">59</td>
<td align="right">161</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.6</td>
<td>$8.5</td>
<td>$8.5</td>
<td>$120.00</td>
<td>$63.7K</td>
<td align="right">55</td>
<td align="right">312</td>
</tr>
<tr>
<td>TTD</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$4.8</td>
<td>$4.6</td>
<td>$4.7</td>
<td>$110.00</td>
<td>$47.0K</td>
<td align="right">59</td>
<td align="right">423</td>
</tr>
</tbody>
</table>
</p>
<h3>About Trade Desk</h3>
<p>The Trade Desk provides a self-service platform that helps advertisers and ad agencies programmatically find and purchase digital ad inventory (display, video, audio, and social) on different devices like computers, smartphones, and connected TVs. It utilizes data to optimize the performance of ad impressions purchased. The firm's platform is referred to as a demand-side platform in the digital ad industry. The firm generates its revenue from fees based on a percentage of what its clients spend on advertising.</p>
<p>In light of the recent options history for Trade Desk, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Trade Desk Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 528,990, with TTD's price down by -2.3%, positioned at $122.14.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 52 days.</li>
</ul>
<h3>What The Experts Say On Trade Desk</h3>
<p>In the last month, 4 experts released ratings on this stock with an average target price of $139.5.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Wedbush has revised its rating downward to Outperform, adjusting the price target to $135.<br />
&#x2A; In a cautious move, an analyst from Scotiabank downgraded its rating to Sector Outperform, setting a price target of $133.<br />
&#x2A; An analyst from Truist Securities persists with their Buy rating on Trade Desk, maintaining a target price of $155.<br />
&#x2A; An analyst from Wedbush downgraded its action to Outperform with a price target of $135. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Trade Desk, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Options

Markets

Trade Desk's Options Frenzy: What You Need to Know

<p>Investors with significant funds have taken a bullish position in TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>), a development that retail traders should be aware of.</p>
<p>This was brought to our attention today through our monitoring of publicly accessible options data at Benzinga. The exact nature of these investors remains a mystery, but such a major move in TMDX usually indicates foreknowledge of upcoming events.</p>
<p>Today, Benzinga's options scanner identified 9 options transactions for TransMedics Gr. This is an unusual occurrence. The sentiment among these large-scale traders is mixed, with 33% being bullish and 33% bearish. Of all the options we discovered, 8 are puts, valued at $933,494, and there was a single call, worth $25,600.</p>
<h3>Projected Price Targets</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $60.0 and $135.0 for TransMedics Gr, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in TransMedics Gr's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to TransMedics Gr's substantial trades, within a strike price spectrum from $60.0 to $135.0 over the preceding 30 days.</p>
<h3>TransMedics Gr 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968723_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$78.0</td>
<td>$73.2</td>
<td>$75.0</td>
<td>$135.00</td>
<td>$300.0K</td>
<td align="right">2</td>
<td align="right">40</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>07/18/25</td>
<td>$73.9</td>
<td>$73.8</td>
<td>$73.8</td>
<td>$135.00</td>
<td>$244.0K</td>
<td align="right">43</td>
<td align="right">33</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/19/25</td>
<td>$32.5</td>
<td>$28.9</td>
<td>$28.91</td>
<td>$80.00</td>
<td>$144.5K</td>
<td align="right">141</td>
<td align="right">50</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$47.8</td>
<td>$43.6</td>
<td>$45.56</td>
<td>$100.00</td>
<td>$82.0K</td>
<td align="right">37</td>
<td align="right">18</td>
</tr>
<tr>
<td>TMDX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$20.0</td>
<td>$18.0</td>
<td>$20.0</td>
<td>$65.00</td>
<td>$80.0K</td>
<td align="right">89</td>
<td align="right">40</td>
</tr>
</tbody>
</table>
</p>
<h3>About TransMedics Gr</h3>
<p>TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.</p>
<h3>Present Market Standing of TransMedics Gr</h3>
<ul>
<li>With a trading volume of 288,303, the price of TMDX is up by 1.87%, reaching $62.85.</li>
<li>Current RSI values indicate that the stock is may be approaching oversold.</li>
<li>Next earnings report is scheduled for 63 days from now.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for TransMedics Gr with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


TMDX

Market Whales and Their Recent Bets on TMDX Options

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Nike</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NKE#NYSE">NKE</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether this is an institution or just a wealthy individual, we don't know. But when something this big happens with NKE, it often means somebody knows something is about to happen.</p>
<p>Today, Benzinga's options scanner spotted 13 options trades for Nike.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 46% bullish and 46%, bearish.</p>
<p>Out of all of the options we uncovered, 12 are puts, for a total amount of $626,297, and there was 1 call, for a total amount of $36,670.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $70.0 to $100.0 for Nike during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Nike's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Nike's substantial trades, within a strike price spectrum from $70.0 to $100.0 over the preceding 30 days.</p>
<h3>Nike Option Activity Analysis: Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734968717_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$22.15</td>
<td>$21.8</td>
<td>$21.8</td>
<td>$100.00</td>
<td>$183.1K</td>
<td align="right">4</td>
<td align="right">84</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.25</td>
<td>$8.34</td>
<td>$85.00</td>
<td>$55.8K</td>
<td align="right">477</td>
<td align="right">204</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$8.45</td>
<td>$8.3</td>
<td>$8.3</td>
<td>$85.00</td>
<td>$55.6K</td>
<td align="right">477</td>
<td align="right">271</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$6.5</td>
<td>$6.25</td>
<td>$6.25</td>
<td>$82.50</td>
<td>$55.0K</td>
<td align="right">324</td>
<td align="right">176</td>
</tr>
<tr>
<td>NKE</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$18.25</td>
<td>$17.65</td>
<td>$18.17</td>
<td>$95.00</td>
<td>$50.8K</td>
<td align="right">20</td>
<td align="right">29</td>
</tr>
</tbody>
</table>
</p>
<h3>About Nike</h3>
<p>Nike is the largest athletic footwear and apparel brand in the world. Key categories include basketball, running, and football (soccer). Footwear generates about two thirds of its sales. Its brands include Nike, Jordan (premium athletic footwear and clothing), and Converse (casual footwear). Nike sells products worldwide through company-owned stores, franchised stores, and third-party retailers. The firm also operates e-commerce platforms in more than 40 countries. Nearly all its production is outsourced to contract manufacturers in more than 30 countries. Nike was founded in 1964 and is based in Beaverton, Oregon.</p>
<p>Having examined the options trading patterns of Nike, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Current Position of Nike</h3>
<ul>
<li>Trading volume stands at 3,639,215, with NKE's price down by -0.08%, positioned at $76.88.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 87 days.</li>
</ul>
<h3>Professional Analyst Ratings for Nike</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $77.4.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Consistent in their evaluation, an analyst from Stifel keeps a Hold rating on Nike with a target price of $75.<br />
&#x2A; An analyst from Needham has revised its rating downward to Buy, adjusting the price target to $84.<br />
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Nike, targeting a price of $73.<br />
&#x2A; An analyst from Deutsche Bank persists with their Buy rating on Nike, maintaining a target price of $82.<br />
&#x2A; An analyst from UBS has decided to maintain their Neutral rating on Nike, which currently sits at a price target of $73. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Nike with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Nike Unusual Options Activity

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Jefferies analyst David Stanton downgraded the rating for <strong>Mesoblast Limited</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) from Buy to Hold. Mesoblast shares closed at $14.63 on Friday. <a href="https://www.benzinga.com/quote/MESO/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>William Blair analyst Sami Corwin downgraded <strong>Applied Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APLT#NASDAQ">APLT</a>) from Outperform to Market Perform. Applied Therapeutics shares closed at $0.8801 on Friday. <a href="https://www.benzinga.com/quote/APLT/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BTIG analyst Thomas Catherwood downgraded the rating for <strong>Innovative Industrial Properties, Inc.</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IIPR#NYSE">IIPR</a>) from Buy to Neutral. NCR Atleos shares closed at $73.66 on Friday. <a href="https://www.benzinga.com/quote/IIPR/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying MESO stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png" alt="" class="wp-image-704457" style="width:578px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193-768x442.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23104327/image-193.png 1085w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


News

Downgrades

Analyst Ratings

Trading Ideas

APLT

IIPR

MESO

This Mesoblast Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Monday

SOUN

SoundHound AI Option Alert: Jan 3 $21 Calls Sweep (21) Near The Ask: 483 @ $2.401 Vs 834 OI; Ref=$20.83

<p>Shares of autonomous driving technology leader <strong>Pony AI Inc</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) <a href="https://www.benzinga.com/24/11/42228142/symbotic-unusual-machines-vci-global-pony-ai-tesla-why-these-5-stocks-are-on-investors-radars-today">debuted on Nasdaq in November</a>.</p>
<p>The Fremont, California-based company has the largest fleet of Level 4 autonomous mobility, offering robotaxi and robotruck services across China, according to Goldman Sachs.</p>
<p><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/635ac86c2048c300015a37cd/allen-chang">Analyst <strong>Allen Chang</strong></a> initiated coverage of Pony AI with a Buy rating and a price target of $19.60.</p>
<p><strong>The </strong><strong>Pony AI</strong><strong> Thesis:</strong> The company is the first to operate completely driverless robotaxis in four tier-1 cities in China, having obtained regulatory permits for providing robotaxi services to the general public, Chang said in the initiation note.</p>
<p><strong>Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a></strong>.</p>
<p>While competition is a concern, it will take time for other companies to develop a vehicle that does not need any safety drivers to offer a better riding experience to passengers versus traditional taxis, the analyst stated. </p>
<p>"Besides, it also takes time to accumulate autonomous driving mileage / track record to earn the operation license from governments," he added.</p>
<p>"Pony AI continues to make progress on robotaxi commercialization, and we expect a revenue CAGR of 27% in 2024-27E on ramp up of its robotaxi fleet operation and start of licenses fee contribution from robotaxi solutions, then a 158% CAGR over 2027-30E with accelerated scale expansion, driving EBITDA and NI to turn positive in 2030E," Chang further wrote.</p>
<p><strong>Price Action:</strong> Shares of Pony AI had risen by 4.48% to $13.75 at the time of publication on Monday.</p>
<p><strong>Read More: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/24/11/42230178/chinas-robotaxi-firm-looks-to-diversify-supply-chain-as-nasdaq-debut-sees-disappointment-amid-global-competition-with-tesla-waymo-and-amazon">China&#8217;s Robotaxi Firm Pony AI Looks To Diversify Supply Chain After Nasdaq Debut, Growing Competition With Tesla, Waymo, And Amazon</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Analyst Color

Long Ideas

Initiation

Movers

PONY

Pony AI Speeds Past Competitors, Commercializes Fully Driverless Vehicles

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Scotiabank analyst Sung Ji Nam initiated coverage on <strong>Thermo Fisher Scientific Inc</strong>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) with a Sector Perform rating and announced a price target of $605. Thermo Fisher Scientific shares closed at $524.05 on Friday. <a href="https://www.benzinga.com/quote/TMO/analyst-ratings">See how other analysts view this stock.</a></li>
<li>Goldman Sachs analyst Allen Chang initiated coverage on <strong>Pony AI Inc</strong>. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) with a Buy rating and announced a price target of $19.6. Pony AI shares closed at $13.16 on Friday. See how other analysts view this stock.</li>
<li>Compass Point analyst Dominick Gabriele initiated coverage on <strong>NCR Atleos Corporation</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NATL#NYSE">NATL</a>) with a Buy rating and announced a price target of $57. NCR Atleos shares closed at $32.33 on Friday. <a href="https://www.benzinga.com/quote/NATL/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>D. Boral Capital analyst Jason Kolbert initiated coverage on <strong>Omeros Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OMER#NASDAQ">OMER</a>) with a Buy rating and announced a price target of $36. Omeros shares closed at $10.31 on Friday. <a href="https://www.benzinga.com/quote/OMER/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Alliance Global Partners analyst Aaron Grey initiated coverage on <strong>Worksport Ltd.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WKSP#NASDAQ">WKSP</a>) with a Buy rating and announced a price target of $2. Worksport shares closed at $0.8465 on Thursday. <a href="https://www.benzinga.com/quote/WKSP/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
<p>Considering buying OMER stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="573" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png" alt="" class="wp-image-704444" style="width:622px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-1024x573.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-300x168.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192-768x430.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23103558/image-192.png 1102w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


NATL

OMER

WKSP

This Omeros Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday

RELI

Reliance Global Shares Resume Trade

Reliance Global Shares Halted On Circuit Breaker To The Upside, Stock Now Up 290.8%

DRCT

Direct Digital Shares Resume Trade Then Again Halted On Circuit Breaker To The Upside, Stock Now Up 183.6%

<p><a href="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars" title="https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars">https://www.theinformation.com/articles/openai-nvidia-and-their-rivals-expand-ai-turf-wars</a></p>
<p>&nbsp;</p>
<p>Nvidia Aims To Rival AWS With Cloud Services And Software Business; OpenAI Develops Server Chips And Browser To Reduce Nvidia And Google Dependence; Elon Musk Builds Massive Supercomputing Cluster For Conversational AI; Major Tech Firms Race To Expand AI Hardware And Software Stacks Amid Intensifying Competition And Efforts To Reduce Supplier Reliance</p>


MSFT

NVDA

'OpenAI, Nvidia And Their Rivals Expand AI Turf Wars' - The Information

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Boeing</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BA, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 29 uncommon options trades for Boeing.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 55% bullish and 37%, bearish.</p>
<p>Out of all of the special options we uncovered, 6 are puts, for a total amount of $323,005, and 23 are calls, for a total amount of $880,234.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $140.0 to $200.0 for Boeing over the recent three months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Boeing's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Boeing's significant trades, within a strike price range of $140.0 to $200.0, over the past month.</p>
<h3>Boeing 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967838_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$36.5</td>
<td>$30.9</td>
<td>$30.9</td>
<td>$200.00</td>
<td>$154.5K</td>
<td>1.7K</td>
<td align="right">0</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/03/25</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$185.00</td>
<td>$113.9K</td>
<td>1.2K</td>
<td align="right">821</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$10.8</td>
<td>$10.55</td>
<td>$10.55</td>
<td>$170.00</td>
<td>$52.7K</td>
<td>11.1K</td>
<td align="right">85</td>
</tr>
<tr>
<td>BA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$4.3</td>
<td>$4.25</td>
<td>$4.25</td>
<td>$150.00</td>
<td>$50.1K</td>
<td>2.8K</td>
<td align="right">812</td>
</tr>
<tr>
<td>BA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/19/25</td>
<td>$48.2</td>
<td>$47.7</td>
<td>$48.2</td>
<td>$140.00</td>
<td>$48.2K</td>
<td>103</td>
<td align="right">10</td>
</tr>
</tbody>
</table>
</p>
<h3>About Boeing</h3>
<p>Boeing is a major aerospace and defense firm. It operates in three segments: commercial airplanes; defense, space, and security; and Global services. Boeing's commercial airplanes segment competes with Airbus in the production of aircraft that can carry more than 130 passengers. Boeing's defense, space, and security segment competes with Lockheed, Northrop, and several other firms to create military aircraft, satellites, and weaponry. Global services provides aftermarket support to airlines.</p>
<p>In light of the recent options history for Boeing, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Present Market Standing of Boeing</h3>
<ul>
<li>With a volume of 1,879,101, the price of BA is down -0.28% at $176.86. </li>
<li>RSI indicators hint that the underlying stock may be overbought.</li>
<li>Next earnings are expected to be released in 37 days.</li>
</ul>
<h3>What Analysts Are Saying About Boeing</h3>
<p>In the last month, 1 experts released ratings on this stock with an average target price of $190.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from JP Morgan has decided to maintain their Overweight rating on Boeing, which currently sits at a price target of $190. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Boeing with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Check Out What Whales Are Doing With Boeing

Direct Digital Holdings Shares Halted To The Upside; Stock Now Up 143.64%

<p>Investors with a lot of money to spend have taken a bearish stance on <strong>ServiceNow</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NOW#NYSE">NOW</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with NOW, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 14 uncommon options trades for ServiceNow.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 21% bullish and 64%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $130,910, and 11 are calls, for a total amount of $1,080,381.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $230.0 to $1140.0 for ServiceNow over the last 3 months. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>In today's trading context, the average open interest for options of ServiceNow stands at 47.88, with a total volume reaching 98.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in ServiceNow, situated within the strike price corridor from $230.0 to $1140.0, throughout the last 30 days.</p>
<h3>ServiceNow Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967832_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th align="right"><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>06/20/25</td>
<td>$280.6</td>
<td>$272.5</td>
<td>$272.5</td>
<td>$850.00</td>
<td>$545.0K</td>
<td align="right">49</td>
<td align="right">20</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$861.7</td>
<td>$848.5</td>
<td>$855.58</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$862.1</td>
<td>$855.3</td>
<td>$855.3</td>
<td>$230.00</td>
<td>$85.5K</td>
<td align="right">12</td>
<td align="right">1</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$399.8</td>
<td>$393.8</td>
<td>$397.93</td>
<td>$700.00</td>
<td>$79.5K</td>
<td align="right">11</td>
<td align="right">2</td>
</tr>
<tr>
<td>NOW</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$321.8</td>
<td>$315.6</td>
<td>$315.6</td>
<td>$860.00</td>
<td>$63.1K</td>
<td align="right">80</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About ServiceNow</h3>
<p>ServiceNow Inc provides software solutions to structure and automate various business processes via a SaaS delivery model. The company primarily focuses on the IT function for enterprise customers. ServiceNow began with IT service management, expanded within the IT function, and more recently directed its workflow automation logic to functional areas beyond IT, notably customer service, HR service delivery, and security operations. ServiceNow also offers an application development platform as a service.</p>
<p>In light of the recent options history for ServiceNow, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>ServiceNow's Current Market Status</h3>
<ul>
<li>Trading volume stands at 86,368, with NOW's price down by -1.13%, positioned at $1078.87.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 30 days.</li>
</ul>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for ServiceNow, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Check Out What Whales Are Doing With NOW

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Exxon Mobil</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XOM#NYSE">XOM</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with XOM, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Exxon Mobil.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 22% bullish and 22%, bearish.</p>
<p>Out of all of the special options we uncovered, 4 are puts, for a total amount of $141,045, and 5 are calls, for a total amount of $265,371.</p>
<h3>Expected Price Movements</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $42.5 and $115.0 for Exxon Mobil, spanning the last three months.</p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Exxon Mobil's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Exxon Mobil's whale activity within a strike price range from $42.5 to $115.0 in the last 30 days. </p>
<h3>Exxon Mobil Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967826_0.png" alt="Options Call Chart" /></p>
<h3>Significant Options Trades Detected:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th align="right"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$5.5</td>
<td>$5.35</td>
<td>$5.5</td>
<td>$105.00</td>
<td>$100.1K</td>
<td>2.6K</td>
<td align="right">186</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$65.25</td>
<td>$61.1</td>
<td>$63.13</td>
<td>$42.50</td>
<td>$63.1K</td>
<td>3</td>
<td align="right">0</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$7.0</td>
<td>$6.9</td>
<td>$6.95</td>
<td>$110.00</td>
<td>$49.3K</td>
<td>16.0K</td>
<td align="right">58</td>
</tr>
<tr>
<td>XOM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>02/21/25</td>
<td>$8.1</td>
<td>$7.95</td>
<td>$8.02</td>
<td>$100.00</td>
<td>$40.1K</td>
<td>837</td>
<td align="right">50</td>
</tr>
<tr>
<td>XOM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>02/21/25</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$6.92</td>
<td>$110.00</td>
<td>$34.6K</td>
<td>16.0K</td>
<td align="right">52</td>
</tr>
</tbody>
</table>
</p>
<h3>About Exxon Mobil</h3>
<p>ExxonMobil is an integrated oil and gas company that explores for, produces, and refines oil around the world. In 2023, it produced 2.4 million barrels of liquids and 7.7 billion cubic feet of natural gas per day. At the end of 2023, reserves were 16.9 billion barrels of oil equivalent, 66% of which were liquids. The company is one of the world's largest refiners with a total global refining capacity of 4.5 million barrels of oil per day and is one of the world's largest manufacturers of commodity and specialty chemicals.</p>
<p>Following our analysis of the options activities associated with Exxon Mobil, we pivot to a closer look at the company's own performance.</p>
<h3>Where Is Exxon Mobil Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,980,999, with XOM's price down by -0.4%, positioned at $105.45.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 39 days.</li>
</ul>
<h3>Expert Opinions on Exxon Mobil</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $123.2.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from RBC Capital downgraded its action to Sector Perform with a price target of $115.<br />
&#x2A; An analyst from RBC Capital persists with their Sector Perform rating on Exxon Mobil, maintaining a target price of $115.<br />
&#x2A; An analyst from Piper Sandler persists with their Overweight rating on Exxon Mobil, maintaining a target price of $127.<br />
&#x2A; Consistent in their evaluation, an analyst from JP Morgan keeps a Overweight rating on Exxon Mobil with a target price of $125.<br />
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Neutral rating for Exxon Mobil, targeting a price of $134. </p>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Exxon Mobil, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Smart Money Is Betting Big In XOM Options

<p>Imperial Oil (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/IMO#AMEX">IMO</a>) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 18.39%. Currently, Imperial Oil has a market capitalization of $32.81 billion. </p>
<p><strong>Buying $1000 In IMO:</strong> If an investor had bought $1000 of IMO stock 5 years ago, it would be worth <strong>$2,314.74</strong> today based on a price of $61.23 for IMO at the time of writing.</p>
<h3>Imperial Oil's Performance Over Last 5 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734967823_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


If You Invested $1000 In This Stock 5 Years Ago, You Would Have This Much Today

<p>Kevin O&#8217;Leary, the well-known entrepreneur and <a href="https://www.benzinga.com/news/24/12/42559810/people-think-kevin-oleary-is-the-mean-shark-but-he-says-im-not-mean-i-just-tell-the-truth-to-keep-families-from-going-broke">investor from Shark Tank</a>, has weighed in on why so many tech CEOs and business leaders are suddenly cozying up to President-elect Donald Trump. During a recent <a href="https://www.youtube.com/watch?v=oML1qbX1_uM">interview</a> on Fox &amp; Friends, O&#8217;Leary said it's not just about Trump's corporate tax policies – the real reason is deregulation.</p>
<p>For context, Trump's policies, such as maintaining the 21% corporate tax rate, undoubtedly appeal to businesses. However, according to O'Leary, the bigger draw is Trump's commitment to cutting federal red tape, making it easier for businesses to grow and operate without constant legal battles and administrative hurdles.</p>
<p><strong>Don't Miss:</strong></p>
<ul>
<li><strong>Can you guess how many Americans successfully retire with $1,000,000 saved?<a href="https://www.benzinga.com/money/1milsaved"><strong> The percentage may shock you</strong></a>.</strong></li>
<li><strong>‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>You can invest today for just $0.26/share with a $1000 minimum.</strong></a></strong></li>
</ul>
<p>O&#8217;Leary pointed out that federal deregulation under Trump's administration is particularly attractive to companies involved in <a href="https://www.benzinga.com/calendars/m-a">mergers and acquisitions</a>. He noted that Trump will "cool off all these pursuits and change many of the administrative rules that make it harder to get things done."</p>
<p>In simple terms, businesses see Trump as someone who will make it easier for them to operate without worrying about constant interference from regulators. That's a huge selling point for companies looking to expand or innovate.</p>
<h2 class="wp-block-heading">CEOs See Trump as &#8216;The Guy&#8217;</h2>
<p>O&#8217;Leary was direct about why CEOs are eager to meet with Trump. &#8220;They're not stupid,&#8221; he said. &#8220;They're saying, &#8216;Well, I think I'm going to go suck up with him because he's the guy for sure for the next two years.'&#8221;</p>
<p><strong>See Also: The global games market is projected to generate $272B by the end of the year —<a href="https://www.benzinga.com/money/gameflip"><strong> </strong><strong>for $0.55/share, this VC-backed startup with a 7M+ userbase gives investors easy access to this asset market.</strong></a></strong></p>
<p>This isn't just about tech leaders like Mark Zuckerberg or Jeff Bezos. O&#8217;Leary said leaders from various industries – and even other countries – are lining up to meet with Trump, recognizing his influence and power in shaping business policy.</p>
<h2 class="wp-block-heading">Donations for Trump&#8217;s Inauguration</h2>
<p>Mark Zuckerberg and <a href="https://www.benzinga.com/tech/24/12/42479253/jeff-bezos-amazon-pledges-1-million-to-trumps-inaugural-event-following-in-the-footsteps-of-mark-zuckerberg-and-meta">Jeff Bezos have each contributed $1 million</a> through their companies, Meta Platforms and Amazon. OpenAI CEO Sam Altman is joining them, making a <a href="https://www.benzinga.com/news/management/24/12/42485193/sam-altman-to-donate-1m-to-trumps-inauguration-fund-following-zuckerberg-bezos-eager-to-support">personal donation of $1 million</a>. Perhaps surprisingly, the trading platform Robinhood has donated $2 million.</p>
<p>O&#8217;Leary highlighted that these donations represent a shift in attitude among business leaders. This is about aligning with Trump's vision for the economy and acknowledging his dominance in shaping the future of policy.&nbsp;</p>
<p><strong>Trending: It&#8217;s no wonder Jeff Bezos holds over $70 million in art — <a href="https://www.benzinga.com/money/masterworks"><strong>this alternative asset has outpaced the S&amp;P 500 since 1995, delivering an average annual return of 11.4%. Here&#8217;s how everyday investors are getting started.</strong></a></strong></p>
<p>Altman, for instance, has publicly praised Trump's commitment to advancing AI infrastructure, a sentiment echoed by other tech leaders. &#8220;President Donald Trump will lead our country into the age of AI and I am eager to support his efforts to ensure America stays ahead,&#8221; he said.</p>
<p>The President-elect&#8217;s ability to remove regulatory roadblocks has made him an attractive ally for business leaders, regardless of their personal opinions about him.</p>
<h2 class="wp-block-heading">Why Deregulation Can Be Harmful</h2>
<p>While <a href="https://www.benzinga.com/markets/equities/24/11/42383725/trump-administrations-deregulation-efforts-to-lift-energy-oil-and-gas-sectors-ai-frenzy-to-aid-faang-stocks-and-nvidia-says-fintech-insider">deregulation is a win for businesses</a>, it can also result in significant drawbacks. <a href="https://www.imf.org/external/pubs/ft/wp/2013/wp13247.pdf">Reduced oversight</a> often opens the door to harmful practices, such as environmental damage, compromised safety standards and unfair labor practices. It can also mean fewer consumer protections, which could let businesses focus more on profits than on doing what's right for people.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv"><strong>The percentage may shock you</strong></a>.</strong></li>
<li><strong>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2"><strong>with $1,000 you can invest at just $0.26/share!</strong></a></strong></li>
</ul>


Kevin O'Leary Says Deregulation Is The Real Reason Everybody Is 'Sucking Up To Trump Now,' Not Lower Taxes

<p>Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.</p>
<ul>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>Weyerhaeuser Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WY#NYSE">WY</a>) from Market Perform to Outperform and announced a $32 price target. Weyerhaeuser shares closed at $27.50 on Friday. <a href="https://www.benzinga.com/quote/WY/analyst-ratings">See how other analysts view this stock.</a></li>
<li>HC Wainwright &amp; Co. analyst Raghuram Selvaraju upgraded the rating for <strong>Aclaris Therapeutics, Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACRS#NASDAQ">ACRS</a>) from Neutral to Buy and maintained the price target of $20. Aclaris Therapeutics shares closed at $2.72 on Friday. See how other analysts view this stock.</li>
<li>Piper Sandler analyst Crispin Love upgraded <strong>GCM Grosvenor Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCMG#NASDAQ">GCMG</a>) from Neutral to Overweight and raised the price target from $12.5 to $14. GCM Grosvenor shares closed at $11.75 on Friday. <a href="https://www.benzinga.com/quote/GCMG/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Raymond James analyst Buck Horne upgraded the rating for <strong>PotlatchDeltic Corporation</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCH#NASDAQ">PCH</a>) from Market Perform to Outperform and announced a $45 price target. PotlatchDeltic shares closed at $38.75 on Friday. <a href="https://www.benzinga.com/quote/PCH/analyst-ratings">See how other analysts view this stock</a>.</li>
</ul>
<p>Considering buying WY stock? Here&#8217;s what analysts think: </p>
<p><figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="592" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png" alt="" class="wp-image-704426" style="width:637px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-1024x592.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191-768x444.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/23102908/image-191.png 1078w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure></p>
<p><strong>Read This Next: </strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/12/42616196/jim-cramer-likes-walmart-recommends-buying-this-very-very-good-financial-stock">Jim Cramer Likes Walmart, Recommends Buying This &#8216;Very, Very Good&#8217; Financial Stock</a></strong></li>
</ul>


Upgrades

Price Target

ACRS

GCMG

This Weyerhaeuser Analyst Turns Bullish; Here Are Top 4 Upgrades For Monday

<p><strong>Rumble Inc.</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RUM#NASDAQ">RUM</a>) shares are trading higher Monday after the company announced it entered into a definitive agreement for a $775 million strategic investment from <a href="https://www.benzinga.com/24/12/42634166/rumble-stock-soars-on-775-million-investment-from-tether-what-to-know"><strong>Tether</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">USDT</a>)</a>.</p>
<p><strong>The Details:</strong> Rumble on Friday announced that Tether plans to buy 103.33 million shares of its common stock for $7.50 per share, representing $775 million in gross proceeds. Tether offers the most widely used dollar <a href="https://www.benzinga.com/topic/stablecoins">stablecoin</a> with more than 350 million users. </p>
<p>Rumble plans to use $250 million of the gross proceeds to support growth initiatives, while the remaining funds will be used for a self-tender offer of up to 70 million Rumble shares at the same price as Tether&#8217;s investment.</p>
<p>Rumble CEO <strong>Chris Pavlovski</strong> does not intend to sell more than 10 million shares of common stock in the tender offer. He will retain his controlling stake in the company.</p>
<p>&#8220;I could not be more excited about this collaboration with Tether for a number of reasons. First, many people may not realize the incredibly strong connection between the cryptocurrency and free speech communities, which is rooted in a passion for freedom, transparency, and decentralization,&#8221; Pavlovski said.</p>
<p>&#8220;Second, the immediate commitment of adding $250 million in cash to our balance sheet not only confirms the level of support and commitment to a collaboration between our companies, it also fuels our growth initiatives. And, third, this transaction provides an immediate liquidity event for all of our stockholders who elect to participate in the self tender offer.&#8221;</p>
<p>Rumble&#8217;s existing board and governance structure, including Pavlovski&#8217;s super-majority voting control, will remain unchanged following the closing of the transaction. </p>
<p>Tether will own a minority position in Rumble&#8217;s outstanding common stock, but will not have the right to designate any members of the board. The investment and tender offer are expected to close during the first quarter of 2025. </p>
<p><strong>Related Link: <a href="https://www.benzinga.com/24/12/42647650/palantir-vs-lockheed-a-tech-fueled-showdown-in-the-850-billion-defense-market">Palantir Vs. Lockheed: A Tech-Fueled Showdown In The $850 Billion Defense Market</a></strong></p>
<p><strong>RUM Price Action</strong>: At the time of writing, Rumble shares were up 79.8% at $12.92, according to data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.</p>
<p><em>Image: Shutterstock.</em></p>


$USDT

Rumble Stock Is Ripping Higher Monday: What's Going On?

<p>Truist Securities  analyst Joon Lee   maintains Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and lowers the price target from $550 to $460.</p>


VRTX

Truist Securities Maintains Buy on Vertex Pharmaceuticals, Lowers Price Target to $460

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>One of the oldest maxims in investing is that higher risk produces greater returns. That maxim holds particularly true across penny <a href="https://investorplace.com/industries/healthcare/biotech/">biotech stocks.</a> Developing therapeutics to cure diseases is a complex business model fraught with the potential to fail at many points.&nbsp;</p>



<p>Developmental and regulatory time frames are long, introducing multiple potential points of failure. The capital necessary for research and development is substantial. So on and so forth. The result is that many&nbsp;upstart biotech firms fail to commercialize, taking their equity down in the process.</p>



<p>Those firms that make it through and reach commercialization are rewarded with the spoils of success. They pay shareholders handsomely with returns that can turn a small investment into a fortune. The firms discussed below still have reasonable chances of commercialization and the potential to reward investors handsomely. Even if they don&rsquo;t ultimately reach success, they can still reward investors handsomely as they pass milestones in the development process.</p>



<h2>FibroGen (FGEN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/04/pte_biotech_1600-300x169.png" alt="Medical technology network team meeting concept. Doctor hand working smart phone modern digital tablet laptop computer graphics chart interface, sun flare effect photo, PTE"><div>Source: everything possible / Shutterstock.com</div></div><p><strong>FibroGen</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/fgen-stock-quote/"><strong>FGEN</strong></a></span>) continues on the path toward commercialization for multiple drugs, targeting multiple diseases. The firm&rsquo;s leading candidate drugs include Pamrevlumab, Roxadustat and several other oncology therapeutics.</p>



<p>Pamrevlumab is currently in Phase 3 clinical trials for the treatment of a certain form of pancreatic cancer. It is also concurrently being studied in phase 2/3&nbsp;clinical studies for metastatic pancreatic cancer. Roxadustat is a drug that induces the production of red blood cells and is approved in multiple countries for use in treating anemia in chronic kidney disease populations. A supplemental New Drug Application (sNDA) has been submitted in China for the drug. It has been accepted for review by the China Health Authority.&nbsp;</p>



<p>One of the more compelling aspects of FibroGen as an investment in financial performance. During the <a href="https://www.globenewswire.com/news-release/2024/05/06/2876129/33525/en/FibroGen-Reports-First-Quarter-2024-Financial-Results.html">first quarter, revenues</a> approached $56 million, up from $36 million a year earlier. The increased revenues allow the company to slash its net losses from $76.7 million to just below $32 million this quarter. Shares currently trade for $1.30 with a <a href="https://stockanalysis.com/stocks/fgen/forecast/">consensus target price of $5</a> and analyst targets ranging as high as $11.</p>



<h2>Nuvectis Pharma (NVCT)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/07/biopharma-1600-300x169.jpg" alt="Illustration of a biopharma company. Doctor standing in front of various medical icons."><div>Source: Billion Photos / Shutterstock</div></div><p><strong>Nuvectis Pharma</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/nvct-stock-quote/"><strong>NVCT</strong></a></span>) is another oncology-oriented biotech stock. It&rsquo;s particularly interesting as a potential investment because while it is in the pre-revenue stages, it is also highly regarded and priced higher than one might expect.</p>



<p>Shares currently trade for $6.21, which is quite high for a pre-revenue biotech firm. Those shares have coverage from a single analyst who expects their value to rise to $22 in the future. Investors who look at the company&rsquo;s financial statements will see that it is basically treading water. NVCT has more than $19 million in liquidity and loses roughly $4 million a quarter on R&amp;D and administrative costs.&nbsp;</p>



<p>The reason for optimism surrounding Nuvectis Pharma is simple: Lead candidate drug <a href="https://www.globenewswire.com/news-release/2024/05/07/2876700/0/en/Nuvectis-Pharma-Inc-Reports-First-Quarter-2024-Financial-Results-and-Business-Highlights.html">NXP800 has been granted</a> fast-track designation by the FDA in platinum-resistant ARID1a-mutated ovarian cancer. It&rsquo;s currently in Phase 1b studies and has the potential to pass through multiple milestones moving forward that, if successful, will reward investors with strong and immediate returns.</p>



<h2>Relmada Therapeutics (RLMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/06/biotechnologyepzm1600-300x169.png" alt="OLK Stock. Modern Medical Research Laboratory: Two Scientists Wearing Face Masks use Microscope, Analyse Sample in Petri Dish, Talk. Advanced Scientific Lab for Medicine, Biotechnology. Blue Color. KZR stock. RSLS stock. Best Biotech Stocks to Buy"><div>Source: Gorodenkoff / Shutterstock.com</div></div><p><strong>Relmada Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/rlmd-stock-quote/"><strong>RLMD</strong></a></span>) is one of many promising late-stage biotech firms developing therapeutics to address diseases of the central nervous system. Those diseases include disorders with high unmet needs including major depressive disorder (MDD), a primary focus of the firm.</p>



<p>REL-1017 is one of the company&rsquo;s lead candidate drugs. The drug is in late-stage development for the treatment of MDD. It is being studied to understand the potential of the drug as a fast-acting, once-daily antidepressant treatment.&nbsp;It is currently being studied in two Phase 3 double placebo-controlled studies.</p>



<p>The company also acquired the rights to a psilocybin and derivatives program&nbsp;in 2021. That program has been rebranded as REL-P11 and is being studied for its efficacy in both neurogenesis and in ameliorating the effects of neurodegenerative conditions.&nbsp;</p>



<p>Psilocybin and other psychoactive drugs are currently a hot area of research. Although Ralmada Therapeutics is in the pre-revenue stages and shares trade for $3.04, the sole analyst with coverage believes those shares could be worth as much as $25 in the future.</p>



<h2>Anixa Biosciences (ANIX)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-1-300x169.jpg" alt="A scientist holds a test tube while it is in a container"><div>Source: Shutterstock</div></div><p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) develops treatments and vaccines to address unmet needs in ovarian cancer and breast cancer. Shares currently trade for less than $3, while the single analyst with coverage believes the stock will <a href="https://www.pricetargets.com/NASDAQ/ANIX/">rise to $12 in value.</a>&nbsp;</p>



<p>The company very <a href="https://www.prnewswire.com/news-releases/anixa-biosciences-commences-treatment-of-fifth-patient-in-ovarian-cancer-car-t-clinical-trial-302150758.html">recently commenced treatment</a> on the 5th patient in an ovarian cancer CAR-T clinical trial. The company is enrolling patients in its first-in-human trial who were unresponsive to at least two prior therapies. Safety was confirmed in the first three-patient cohort. The company is tripling the dose in patients four and five in order to establish dosage tolerability.&nbsp;</p>



<p>The company also recently expanded its partnership with the Cleveland Clinic to develop cancer vaccines. That partnership aims to further the development of vaccines targeting rare and aggressive forms of breast and ovarian cancer. Anixa Biosciences will continue to be an interesting stock for investors, especially in light of strong positive news on multiple fronts.</p>



<h2>Genenta Science (GNTA)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600-min-1-300x169.jpg" alt="an image of a microscope, NEXI stock"><div>Source: Shutterstock</div></div><p>Let&rsquo;s begin discussing<strong> Genenta Science</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/gnta-stock-quote/"><strong>GNTA</strong></a></span>) stock in relation to its safety as an investment overall. Readers have noticed that multiple recommendations above have only one analyst rating. I don&rsquo;t have to explain why that introduces a lot of risk overall. The thing I want to note about Genenta Science is that it has <a href="https://stockanalysis.com/stocks/gnta/forecast/">two target prices,</a> one at $15 and the other at $25. Thus, the consensus price is $20. Genenta Science shares trade at $3.30.</p>



<p>While the company is attractive for its raw return potential, I should also note that there are a lot of unknowns with this company. It is an Italian company and doesn&rsquo;t provide a lot in the way of information. It&rsquo;s a lot easier to find updates on domestic companies. The information we do have is a<a href="https://ir.genenta.com/static-files/db77523d-9bdf-47bd-8120-02eb11e0d7df"> financial report dating from the end of 2023.</a> It simply shows the company is not producing much in the way of revenues.</p>



<p>The stock offers so much potential because the company is developing a stem cell platform for the safe treatment of solid tumors. It has <a href="https://www.globenewswire.com/news-release/2024/02/08/2825783/0/en/Genenta-Demonstrated-Reprogramming-of-the-Tumor-Microenvironment-in-GBM-Patients-Paving-the-Way-for-Innovative-Treatments-of-Solid-Tumors.html">demonstrated the potential</a> to reprogram the cells of glioblastoma patients.&nbsp;</p>



<h2>Affimed (AFMD)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2022/02/red-blood-cells-300x169.jpg" alt="3d rendering red blood cells in vein"><div>Source: Phonlamai Photo / Shutterstock.com</div></div><p><strong>Affimed</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/afmd-stock-quote/"><strong>AFMD</strong></a></span>) continues to develop therapeutics for the treatment of lymphoma, a grouping of blood cancers that originate in the lymphatic system.</p>



<p>The stock is interesting for a number of reasons both operational and developmental. The company reduced <a href="https://www.globenewswire.com/news-release/2024/03/28/2853795/0/en/Affimed-Reports-2023-Financial-Results-and-Operational-Progress.html">its workforce by 50% in 2023</a> in an effort to streamline operations.</p>



<p>AFMD is redirecting its resources to three lead candidate programs following the restructuring. That leads me to my next point: The company is doing well from a developmental perspective. Each of those three candidate programs progressed in 2023. Affimed awaits further data readouts from those programs in Q2 and expects dose escalation. That implies current safety and will be used to establish the upper tolerability for those respective programs.&nbsp;</p>



<p>As with any penny biotech stock, failure is a distinct possibility. However, Affimed is well regarded and benefits from a <a href="https://stockanalysis.com/stocks/afmd/forecast/">consensus target price of $32.</a> It currently trades for just over $4.&nbsp;</p>



<h2>Lipocine (LPCN)</h2>



<div><img width="300" height="169" src="https://investorplace.com/wp-content/uploads/2019/07/biotech1600d-300x169.jpg" alt="Image of two scientists in lab coats studying results in a lab. best biotech stocks to buy"><div>Source: Shutterstock</div></div><p><strong>Lipocine</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/lpcn-stock-quote/"><strong>LPCN</strong></a></span>) stock trades for $6.89 but is expected to rise to $33. Like so many other stocks on this list, Lipocine only has coverage from one analyst. That introduces risk to what is already a risky biotech stock. However, that&rsquo;s the game investors must be willing to play in the risk-fueled world of pharma stock&nbsp;investing.</p>



<p>As you may have guessed by the firm&rsquo;s name, Lipocine does work in the obesity management space. Candidate drug Lpcn2401 is currently in Phase 2 studies and is showing promise in reducing obesity in patients with at least one co-related morbidity.</p>



<p>However, the company is also developing treatments outside of the weight loss realm. Those programs span disease areas, including postpartum depression, cirrhosis, essential tremors and testosterone replacement therapy.&nbsp;</p>



<p>What&rsquo;s particularly good about the company is that it actually produced positive net income in the most recent quarter. Lipocine <a href="https://www.prnewswire.com/news-releases/lipocine-announces-financial-results-for-the-first-quarter-ended-march-31-2024-302140431.html">reported $3.5 million in net income</a> in the first quarter, reversing a $3.9 million net loss 12 months prior.</p>



<p><em><strong>On <a href="https://investorplace.com/stock-types/penny-stocks/">Penny Stocks</a> and Low-Volume Stocks</strong>: With only the rarest exceptions, InvestorPlace does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;penny stocks&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that InvestorPlace.com&rsquo;s writers disclose this fact and warn readers of the risks.</em></p>



<p><em><strong>Read More</strong>: <a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/">Penny Stocks &mdash; How to Profit Without Getting Scammed</a></em></p>



<p><em>On the date of publication, Alex Sirois did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/"><em> Publishing Guidelines.</em></a></p>
<div><p>Alex Sirois is a freelance contributor to InvestorPlace whose personal stock investing style is focused on long-term, buy-and-hold, wealth-building stock picks. Having worked in several industries from e-commerce to translation to education and utilizing his MBA from George Washington University, he brings a diverse set of skills through which he filters his writing.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	
<p>The post <a href="https://investorplace.com/2024/05/7-penny-biotech-stocks-to-triple-your-investment/">7 Penny Biotech Stocks to Triple Your Investment</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

7 Penny Biotech Stocks to Triple Your Investment

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Anixa Biosciences</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/anix-stock-quote/"><strong>ANIX</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Anixa Biosciences reported earnings per share of -10 cents. This was above the analyst estimate for EPS of -11 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/06/anix-stock-earnings-anixa-biosciences-for-q2-of-2024/">ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

ANIX Stock Earnings: Anixa Biosciences Beats EPS for Q2 2024

Anixa Biosciences authorizes $5M share buyback program

Analyst Yi Chen from H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report) and keeping the price target at $7.00. Y...

Buy Rating Affirmed for Anixa Biosciences Amid Promising Cancer Therapy Trials

Analyst Yi Chen of H.C. Wainwright reiterated a Buy rating on Anixa Biosciences (ANIX – Research Report), retaining the price target of $7.00. Yi C...

Buy Rating Affirmed for Anixa Biosciences Amid Promising CAR-T Therapy Trials and Stable Financials

Anixa Biosciences ( ($ANIX) ) has provided an announcement. Anixa Biosciences, in collaboration with Cleveland Clinic, unveiled promising results f...

Anixa Biosciences Reports Promising Phase 1 Vaccine Results

Anixa Biosciences (ANIX) announced that it has dosed its first patient in the third cohort in the ongoing Phase 1 clinical trial of its novel chime...

Anixa Biosciences initiates third cohort in CAR-T clinical trial

Anixa Biosciences (ANIX) announced that its Board of Directors has approved the purchase of Bitcoin as a treasury reserve asset. With Anixa's stron...

Anixa Biosciences board approves purchase of Bitcoin as treasury reserve asset

Anixa rises as board approves Bitcoin as a treasury reserve asset

Anixa Biosciences: Uncertainty In The Pipeline, Uncertainty In Their Financial Outlook

AFMD

ANIX

FGEN

GNTA

LPCN

NVCT

RLMD

Press Releases

Anixa Biosciences Announces Submission of Protocol Amendment for CAR-T Trial

Anixa Biosciences Appoints Suyasha Gupta as Senior Director of Clinical Development

Anixa Biosciences Announces Second Dose Administered to Patient in Ovarian Cancer CAR-T Clinical Trial

Anixa Biosciences and Cleveland Clinic to Present Additional Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Small Cap

Anixa Biosciences to Present at the Sidoti Micro-Cap Virtual Conference on November 13 & 14, 2024

Anixa Biosciences Announces Timing of Public Release of Data from the Phase 1 Study of its Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Anixa Biosciences and Cleveland Clinic Present New Updated Positive Data from Phase 1 Study of Breast Cancer Vaccine at the 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting

Comments

Anixa Biosciences

Interés en corto

Anixa Biosciences (NASDAQ:ANIX) Bolsa, Informe de interés en corto

La gente también mira

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL